Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10038028 | 0.80 | POLB (0.32) | POLBGAAMAPK1NPSR1 | |
| SCHEMBL10068628 | 0.77 | ALDH1A1 (0.54) | SIGMAR1TMEM97TSHRKMT2AMEN1 | |
| SCHEMBL9767683 | 0.66 | POLB (0.40) | SIGMAR1TMEM97CYP2C19POLBGAA | |
| SCHEMBL12221533 | 0.66 | POLB (0.40) | SIGMAR1TMEM97CYP2C19POLBGAA | |
| SCHEMBL7922102 | 0.66 | POLB (0.40) | SIGMAR1TMEM97CYP2C19POLBGAA | |
| SCHEMBL19387511 | 0.66 | MEN1 (0.58) | CYP3A4TSHRCYP2C19KMT2AMEN1 | |
| SCHEMBL6373575 | 0.65 | POLB (0.40) | SIGMAR1TMEM97CYP2C19POLBGAA | |
| SCHEMBL7911469 | 0.65 | POLB (0.40) | SIGMAR1TMEM97CYP2C19POLBGAA | |
| SCHEMBL7921733 | 0.64 | OPRM1 (0.41) | SIGMAR1TMEM97POLBGAAMAPK1 | |
| SCHEMBL25627219 | 0.64 | OPRM1 (0.41) | SIGMAR1TMEM97POLBGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9592497-B2 | Process for the asymmetric hydrogenation of imides | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2017-03-14 | — | — | US | disclosed |
| US-20120165546-A1 | PROCESS FOR THE ASYMMETRIC HYDROGENATION OF IMIDES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2012-06-28 | — | — | US | disclosed |
| WO-2010145024-A1 | PROCESS FOR THE ASYMMETRIC HYDROGENATION OF IMIDES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165546-A1 | PROCESS FOR THE ASYMMETRIC HYDROGENATION OF IMIDES | IDH2, HRH4, HPSE | SIGMAR1 1425/4885TMEM97 3803/4885CYP3A4 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.